2021-003059-41
A randomized, double-blind, placebo-controlled, multicenter trial assessing the reduction of the rate of lipoprotein apheresis after treatment with pelacarsen (TQJ230) compared to placebo in patients with hyperlipoproteinemia(a) and established cardiovascular disease undergoing weekly lipoprotein apheresis in Germany
Novartis Pharma AG·EU Clinical Trials RegisterOngoing
Study focus
- Disease/Condition
- Cardiovascular Disease
Sponsor & location
- Primary sponsor
- Novartis Pharma AG
Timeline & enrollment
- Phase
- N/A
- Start date
- N/A
- End date
- N/A
ICD-10 classifications
Cardiovascular disease, unspecifiedHypertensive heart diseaseHeart disease, unspecifiedAtherosclerotic cardiovascular disease, so describedAtherosclerotic heart disease
Data source
- Registry
- EU Clinical Trials Register
- Trial ID
- 2021-003059-41
- Type
- Non-Device Trial
About this record
Access comprehensive clinical trial information for 2021-003059-41 through Pure Global AI's free database. This phase not specified trial is sponsored by Novartis Pharma AG and is currently Ongoing. The study focuses on Cardiovascular Disease.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to EU Clinical Trials Register data, helping medical device and pharmaceutical companies navigate clinical research efficiently.